The FDA has granted Orphan Drug designation to Surface Oncology’s lead investigational candidate SRF231, a potential treatment for patients with multiple myeloma.
The FDA has granted Orphan Drug designation to Surface Oncology’s lead investigational candidate SRF231, a potential treatment for patients with multiple myeloma.